medium · CFA Level I ethics
Amberfen Pharma is being analyzed by a research analyst who attends a public industry conference. The analyst hears a supplier mention that Amberfen has significantly increased its orders for a specific raw material. Combining this with her own analysis of public clinical trial timelines, she issues a 'Strong Buy' rating. This is:
- A violation of Standard II(A) regarding material nonpublic information.
- Permissible under the mosaic theory.
- A violation of Standard I(C) Misrepresentation if the clinical trial outcomes are not yet guaranteed.
Sign up free to see the explanation and track your rank →
More CFA Level I ethics practice
- If she sells the stock for her personal account before the report is public, she has:
- Vesper Foods Investment Management has a policy to notify all clients of a 'Sell' rating v
- A trader at Vesper Foods learns from an internal IT error that the firm's quarterly revenu
- An advisor at Oakridge Capital is managing an account for hi… — The advisor should treat t
- The trader should:
- Which professional control is mandated for CFA candidates when using AI outputs?
- According to Standard VI(B) Priority of Transactions, which statement best describes Julia
- Under Standard VI(B) Priority of Transactions, the manager should: